Latest news with #Reddy
Hans India
an hour ago
- Business
- Hans India
Sudha Reddy appointed first-ever global ambassador for Miss World Organization
At the 72nd Miss World Festival finale, Hyderabad-based philanthropist and businesswoman Sudha Reddy will be named the first Global Ambassador for the Miss World Organization. This historic appointment recognizes Reddy's enduring commitment to social impact, women's empowerment, and equitable development. As Global Ambassador for 'Beauty WithA Purpose'—the pageant's humanitarian arm—Reddy will lead global outreach, champion critical social initiatives, and spotlight inspiring grassroots change-makers. She will also serve on the jury for Miss World 2025, bringing her global insights to the selection process. Expressing her vision, Reddy stated, 'As Global Ambassador for 'Beauty WithA Purpose,' I am committed to uplifting communities, empowering women, and expanding educational opportunities to foster a more inclusive world.' Miss World Chairperson Julia Morley affirmed, 'Sudha Reddy's philanthropic vision and leadership embody the spirit of 'Beauty WithA Purpose.' Her partnership will drive meaningful change and inspire future leaders.' The event, marking Miss World's return to India after nearly three decades, will see Hyderabad host delegates from over 100 nations. Reddy, director of Megha Engineering & Infrastructures Limited and founder of the Sudha Reddy Foundation, has long been a catalyst for social change through partnerships with UNICEF, Global Gift Foundation, and numerous cultural platforms.
Economic Times
3 hours ago
- Business
- Economic Times
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Live Events Next Hearing on Aug 19 (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
4 hours ago
- Business
- Time of India
Big Fat Legal War Bursts Out aheadof Wegovy Launch
Live Events A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weight-loss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have a licence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide— the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide.'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
4 hours ago
- Business
- Time of India
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is scheduled for August 19. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Next Hearing on Aug 19 A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy semaglutide ) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
New Indian Express
7 hours ago
- Politics
- New Indian Express
Keep state development above party politics
The pugnacious leader that he is, Telangana Chief Minister A Revanth Reddy manages to make it to the headlines often. He is also a shrewd politician who knows it takes two to tango when it comes to developing the state. As a Congressman, his instincts are in sync with that of his party on several issues. Operation Sindoor just happens to be one of those where sensitivity may serve better than sinew. His barbs against the Centre fly like missiles, and his repeated comparison between Indira Gandhi and Prime Minister Narendra Modi resonate with Congress supporters. The other day, he sought to know from the PM how many Rafale fighter aircraft were lost in Operation Sindoor. Politically speaking, he may have thought of bolstering party leader Rahul Gandhi's attacks on the Centre. What is unquestionable is that he went a step farther than even his leader. Defence matters can be tricky material to use for polemics, especially right after a war. Questions do need to be asked, but in a non-partisan way. Reddy may feel himself politically justified in attending Jai Hind rallies, a counter to the BJP's Tiranga rallies. It should be seen within the context of what should be an integrationist moment, though it is unfortunate that both the national parties appear to be politicising Operation Sindoor. It is time to support the armed forces in one voice at a time when the shadow of conflict has not entirely lifted. Reddy may have no compunction in calling a spade a spade, but he is also keenly aware of the imperatives of running a state. Within a fortnight, he had a meeting with the Prime Minister, where he submitted a wishlist, and during that same period he was going for the BJP's jugular. Presumably, he knows how to find his way around a paradox.
